Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Geographic Atrophy of the Macula”

26 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 26 results

Testing effectiveness (Phase 2)Study completedNCT05703867
What this trial is testing

Transpalpebral Microcurrent Stimulation for the Improvement of Visual Acuity in Patients With Macular Degeneration

Who this might be right for
Age-Related Macular DegenerationNonexudative Age-related Macular Degeneration
Jarding, John, OD 404
Early research (Phase 1)Study completedNCT01922128
What this trial is testing

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

Who this might be right for
Nonexudative Age-related Macular Degeneration
MacuCLEAR, Inc. 20
Not applicableLooking for participantsNCT05706896
What this trial is testing

Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma

Who this might be right for
Dry Age-related Macular Degeneration
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 36
Not applicableLooking for participantsNCT06662162
What this trial is testing

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Who this might be right for
Age-Related Macular DegenerationAge-related Macular Degeneration (ARMD)Intermediate AMD+1 more
i-Lumen Scientific AUS PTY LTD 100
Large-scale testing (Phase 3)Ended earlyNCT01601483
What this trial is testing

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

Who this might be right for
Nonexudative Age Related Macular Degeneration
MacuCLEAR, Inc. 22
Large-scale testing (Phase 3)Study completedNCT04005352
What this trial is testing

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 734
Testing effectiveness (Phase 2)Study completedNCT00940407
What this trial is testing

Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration

Who this might be right for
Nonexudative Age-related Macular Degeneration
Merry, Graham, M.D. 18
Not applicableStudy completedNCT02051998
What this trial is testing

Directional Spread in Geographic Atrophy

Who this might be right for
Nonexudative Age-related Macular Degeneration
University Hospital, Bonn 130
Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Testing effectiveness (Phase 2)Study completedNCT00447954
What this trial is testing

An Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration

Who this might be right for
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Neurotech Pharmaceuticals 53
Not applicableStudy completedNCT03242083
What this trial is testing

Evaluate the Quality of Life of Patients With AMD

Who this might be right for
Age-related Macular Degeneration
Centre Hospitalier Universitaire Dijon 28
Not applicableActive Not RecruitingNCT01115387
What this trial is testing

GARM II: A Study on the Genetics of Age-related Maculopathy

Who this might be right for
Age-related Macular DegenerationAge-related Maculopathy
University of California, Los Angeles 603
Testing effectiveness (Phase 2)Active Not RecruitingNCT05839041
What this trial is testing

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Geographic Atrophy of the MaculaMacular Degeneration
Aviceda Therapeutics, Inc. 300
Post-approval studies (Phase 4)Study completedNCT01775124
What this trial is testing

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 332
Testing effectiveness (Phase 2)Looking for participantsNCT06659549
What this trial is testing

Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Who this might be right for
Geographic Atrophy of the Macula
Galimedix Therapeutics Inc 110
Not applicableStudy completedNCT00564902
What this trial is testing

The Zeaxanthin and Visual Function Study

Who this might be right for
Age Related Macular DegenerationCognition Disorders
Chrysantis, Inc. 60
Large-scale testing (Phase 3)Study completedNCT04597632
What this trial is testing

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 248
Large-scale testing (Phase 3)Study completedNCT04264819
What this trial is testing

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals 295
Not applicableLooking for participantsNCT06351657
What this trial is testing

Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression

Who this might be right for
Age-Related Macular DegenerationGeographic Atrophy
Medical University of Vienna 200
Post-approval studies (Phase 4)Study completedNCT05269966
What this trial is testing

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
Novartis Pharmaceuticals 105
Load More Results